Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462760 | 0.90 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22084454 | 0.90 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL23139914 | 0.88 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21780124 | 0.88 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL10929443 | 0.85 | MEN1 (0.42) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL24038852 | 0.85 | MEN1 (0.42) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL14044868 | 0.85 | MEN1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3131272 | 0.85 | TDP1 (0.47) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22416651 | 0.83 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL8295860 | 0.83 | MAOA (0.51) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273235-B2 | Compositions and methods for inhibiting β-lactamase | LEGOCHEM BIOSCIENCES, INC. (KR) | 2019-04-30 | — | — | US | disclosed |
| EP-3356357-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA-LACTAMASE | LegoChem Biosciences, Inc. (KR) | 2018-08-08 | — | — | EP | disclosed |
| US-20180194765-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA-LACTAMASE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-07-12 | — | — | US | disclosed |
| US-9951072-B2 | Compositions and methods for inhibiting beta-lactamase | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-04-24 | — | — | US | disclosed |
| US-20170096430-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA-LACTAMASE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096430-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA-LACTAMASE | LCT, MGAM, PEPD | TDP1 2356/4885MAOA 142/4885MAOB 148/4885 |
| US-20180194765-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA-LACTAMASE | LCT, MGAM, PEPD | TDP1 2356/4885MAOA 142/4885MAOB 148/4885 |
| US-10273235-B2 | Compositions and methods for inhibiting β-lactamase | MGAM, LCT, PEPD | TDP1 2360/4885MAOA 158/4885MAOB 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.